HighTower Advisors LLC Reduces Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

HighTower Advisors LLC lessened its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 54.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,018 shares of the biopharmaceutical company’s stock after selling 46,466 shares during the quarter. HighTower Advisors LLC’s holdings in Dynavax Technologies were worth $441,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 1,685 shares during the period. US Bancorp DE lifted its position in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP bought a new position in shares of Dynavax Technologies during the 3rd quarter valued at approximately $45,000. Nisa Investment Advisors LLC grew its stake in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,679 shares in the last quarter. Finally, Centiva Capital LP bought a new stake in shares of Dynavax Technologies in the 3rd quarter worth about $119,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Down 0.3 %

NASDAQ:DVAX opened at $12.72 on Friday. The company has a market cap of $1.67 billion, a price-to-earnings ratio of 97.85 and a beta of 1.33. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $15.01. The stock has a fifty day simple moving average of $12.24 and a 200-day simple moving average of $11.51. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.